+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06978088

Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated and BTK T474I Mutant Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Led by Zulfa Omer · Updated on 2025-08-14

34

Participants Needed

1

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of LP-168 and obinutuzumab for patients with previously treated Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma CLLSLL and those with a specific BTK T474I gatekeeper mutation. This phase II multicenter study aims to find a safe dosing plan and gather early data on how well the combination works to increase deep response rates, including complete remission and undetectable minimal residual disease MRD. Participants will receive LP-168 orally at 200 mg daily starting from day 1 for 12 cycles, each cycle lasting 28 days. After cycle 6, response will be evaluated by labs, CT scans, and bone marrow biopsy. Starting cycle 7, obinutuzumab is added for 6 cycles alongside LP-168, administered on specific days within each cycle. At the end of cycle 12, therapy will be assessed, and patients with undetectable MRD and complete remission may stop treatment others may continue LP-168 with follow-up every 6 months. During the study, patients undergo regular assessments including labs, imaging, bone marrow exams, and next-generation sequencing to monitor MRD status. Researchers will measure response rates, safety, drug pharmacokinetics, and BTK occupancy. Follow-up for response duration, survival, and safety will continue for up to six years, ensuring detailed monitoring of treatment effects and patient outcomes over time.

CONDITIONS

Brief Title

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Research Team

U

UCCC Clinical Trials Office

Z

Zulf Omer, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here